Drug intelligence / Profile preview

pyridorin

Development stage: Phase 2
Lead developer: Medpace
Modality: Small Molecules
Administration: Oral

Overview

Pyridorin is an investigational small molecule drug developed for the treatment of diabetic nephropathy. It acts as a scavenger of pathogenic oxidative chemistries, targeting and neutralizing reactive oxygen species and other oxidative intermediates that contribute to the progression of kidney damage in diabetes. Pyridorin is designed to slow the progression of diabetic kidney disease by inhibiting these pathological oxidative processes. The drug has been evaluated in Phase 3 clinical trials for its efficacy in reducing renal disease progression in patients with type 2 diabetes and nephropathy[7][10]. Pyridorin is considered a first-in-class compound for this indication.

Brand names: pyridorin
Other names: 4-aminomethyl-5-hydroxy-6-(hydroxymethyl)-2-methylpyridinevitamin B6 (as a form)PM

Beyond the preview

Go deeper on pyridorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pyridorin.

Explore the full profile